Tackling Antimicrobial Resistance in the Shadow of COVID-19
ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic is a challenge for ongoing efforts to combat antimicrobial-resistant (AMR) bacterial infections. As we learn more about COVID-19 disease and drug stewardship evolves, there is likely to be a lasting impact of increased use of antimicrobial ag...
Main Author: | Ami Patel |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2021-08-01
|
Series: | mBio |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/mBio.00473-21 |
Similar Items
-
In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates
by: Ami Patel, et al.
Published: (2024-12-01) -
Editorial: Women in antimicrobial resistance and new antimicrobial drugs
by: Rachel A. F. Wozniak, et al.
Published: (2023-08-01) -
What samples are suitable for monitoring antimicrobial-resistant genes? Using NGS technology, a comparison between eDNA and mrDNA analysis from environmental water
by: Kahoko Takeda-Nishikawa, et al.
Published: (2023-12-01) -
Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge
by: Hyeree Choi, et al.
Published: (2020-04-01) -
Editorial: Antimicrobial resistance in zoonotic bacteria
by: Guyue Cheng, et al.
Published: (2024-01-01)